JAK mutations in high-risk childhood acute lymphoblastic leukemia.

@article{Mullighan2009JAKMI,
  title={JAK mutations in high-risk childhood acute lymphoblastic leukemia.},
  author={Charles G Mullighan and Jinghui Zhang and Richard C Harvey and J. Racquel Collins-Underwood and Brenda A. Schulman and Letha A A Phillips and Sarah K Tasian and Mignon L Loh and Xiaoping Su and Wei Liu and Meenakshi Devidas and Susan R. Atlas and I-Ming Chen and Robert J. Clifford and Daniela S. Gerhard and William L Carroll and Gregory H. Reaman and Malcolm A Smith and James R. Downing and Stephen P Hunger and Cheryl L. Willman},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2009},
  volume={106 23},
  pages={9414-8}
}
Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations. Mutation of genes encoding tyrosine kinases is uncommon in ALL, with the exception of Philadelphia chromosome-positive ALL, where the t(9,22)(q34;q11) translocation encodes the constitutively active BCR-ABL1 tyrosine kinase. We recently identified a poor prognostic subgroup of pediatric BCR… CONTINUE READING
Highly Influential
This paper has highly influenced 21 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 235 extracted citations

Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia

Cellular and Molecular Life Sciences • 2013
View 13 Excerpts
Highly Influenced

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 7 Excerpts
Highly Influenced

Therapeutic Kinase Inhibitors

Current Topics in Microbiology and Immunology • 2012
View 4 Excerpts
Highly Influenced

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 32 references

A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

L Kearney
Blood • 2008

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study

MJ Borowitz
Blood • 2008

Similar Papers

Loading similar papers…